CTLA4 and neoplasm: To this aim, CTLA-4-positive SK-BR-3 tumor cells were co-cultured with enriched NK cells (Effector:Target ratio 3:1) and treated for 24 h in the absence or in the presence of ID-1, ID-8, or Ipilimumab used as a control at the same concentrations.